This story was produced in partnership with DoubleBlind, an independent magazine covering the psychedelic industry. In the spring of 2022, a 49-year-old New Yorker named David* headed south to Cancún, Mexico. He went to overcome his dependency on drugs using ibogaine, the primary alkaloid in a central African root bark …
Read More »Leading the Change: Transforming Psychedelic Healthcare Through Harm Reduction Practices
The future of psychiatric treatment includes psychedelic healthcare. As the negative stigma around psychedelics and cannabis continues to shift, other stigmatized mind-altering medicines have emerged into mainstream culture and healthcare, offering options for addressing difficult mental health concerns, such as depression, anxiety, addiction, post-traumatic stress disorder, obsessive-compulsive disorder, eating disorders …
Read More »